The etiology of hepatocellular carcinoma and consequences for treatment. The oncologist, pp.14-22, 2010. ,
The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011, Liver International, vol.4, issue.Suppl. 4, pp.1053-1063, 2001. ,
DOI : 10.1159/000218339
Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies???mature results of the French Phase II RTF-1 trial, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.4, pp.1152-1158, 2006. ,
DOI : 10.1016/j.ijrobp.2006.06.015
Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patients, Acta Oncologica, vol.33, issue.52, pp.861-870, 1995. ,
DOI : 10.3109/02841869309093624
The Cyberknife: a frameless robotic system for radiosurgery, Stereotact Funct Neurosurg, vol.69, pp.1-4124, 1997. ,
Management of hepatocellular carcinoma: An update, Hepatology, vol.10, issue.Suppl 1, pp.1020-1022, 2011. ,
DOI : 10.1016/S1470-2045(08)70285-7
Implantation of fiducial markers in the liver for stereotactic body radiation therapy: Feasibility and results. Diagn Interv Imaging, 2014. ,
Hepatic toxicity resulting from cancer treatment, International Journal of Radiation Oncology*Biology*Physics, vol.31, issue.5, pp.1237-1248, 1995. ,
DOI : 10.1016/0360-3016(94)00418-K
Radiation-Associated Liver Injury, International Journal of Radiation Oncology*Biology*Physics, vol.76, issue.3, pp.94-100, 2010. ,
DOI : 10.1016/j.ijrobp.2009.06.092
URL : http://europepmc.org/articles/pmc4388033?pdf=render
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 1990. ,
DOI : 10.1016/j.ejca.2008.10.026
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma, Seminars in Liver Disease, vol.30, issue.01, pp.52-60, 2010. ,
DOI : 10.1055/s-0030-1247132
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification, Seminars in Liver Disease, vol.19, issue.03, pp.329-338, 1999. ,
DOI : 10.1055/s-2007-1007122
A model to predict survival in patients with end-stage liver disease, Hepatology, vol.33, issue.2, pp.464-470, 2001. ,
DOI : 10.1053/jhep.2001.22172
Clinical Practice Guidelines: Management of hepatocellular carcinoma, Eur J Cancer. mars, vol.48, issue.5, pp.599-641, 2012. ,
on behalf of the ESMO Guidelines Working Group Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.23, issue.7, pp.41-48, 2012. ,
Is It Time to Adopt External Beam Radiotherapy in the NCCN Guidelines as a Therapeutic Strategy for Intermediate/Advanced Hepatocellular Carcinoma?, Oncology, vol.14, issue.s1, pp.69-74, 2013. ,
DOI : 10.1111/j.1478-3231.2005.01170.x
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version, JSH) 2010 Updated Version, pp.339-364, 2011. ,
DOI : 10.1159/000111702
Hepatobiliary Cancers, Journal of the National Comprehensive Cancer Network, vol.7, issue.4, pp.350-91, 2009. ,
DOI : 10.6004/jnccn.2009.0027
Stereotactic Single-Dose Radiation Therapy of Liver Tumors: Results of a Phase I/II Trial, Journal of Clinical Oncology, vol.19, issue.1, pp.164-70, 2001. ,
DOI : 10.1200/JCO.2001.19.1.164
Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study, Acta Oncologica, vol.62, issue.1, pp.831-837, 2006. ,
DOI : 10.1016/j.ijrobp.2005.01.002
Quality of Life After Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors, International Journal of Radiation Oncology*Biology*Physics, vol.70, issue.5, pp.1447-1452, 2008. ,
DOI : 10.1016/j.ijrobp.2007.08.058
Fractionated Stereotactic Radiotherapy in Patients with Primary Hepatocellular Carcinoma, Japanese Journal of Clinical Oncology, vol.36, issue.3, pp.154-158, 2006. ,
DOI : 10.3109/02841869509127197
Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Journal of Clinical Oncology, vol.26, issue.4, pp.657-664, 2008. ,
DOI : 10.1200/JCO.2007.14.3529
Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies, International Journal of Radiation Oncology*Biology*Physics, vol.78, issue.2, pp.486-493, 2010. ,
DOI : 10.1016/j.ijrobp.2009.08.020
Cyberknife Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results, HPB Surgery, vol.1, issue.1, 2010. ,
DOI : 10.1093/jjco/hyi236
Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis, BMC Cancer, vol.48, issue.1, p.351, 2008. ,
DOI : 10.1016/S0360-3016(00)00748-3
Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma, Journal of Surgical Oncology, vol.76, issue.3, pp.209-214, 2010. ,
DOI : 10.1016/j.ijrobp.2009.02.027
Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization, Cancer, vol.81, issue.21, pp.5424-5431, 2012. ,
DOI : 10.1016/j.ijrobp.2010.07.1986
Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer, BMC Cancer, vol.58, issue.suppl 1, p.475, 2010. ,
DOI : 10.1016/j.ijrobp.2003.08.012
Stereotactic Body Radiation Therapy in Recurrent Hepatocellular Carcinoma, International Journal of Radiation Oncology*Biology*Physics, vol.84, issue.2, pp.355-361, 2012. ,
DOI : 10.1016/j.ijrobp.2011.11.058
High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma, Radiation Oncology, vol.8, issue.1, p.250, 2013. ,
DOI : 10.1016/j.jhep.2012.05.007
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity, PLoS ONE, vol.8, issue.10, p.77472, 2013. ,
DOI : 10.1371/journal.pone.0077472.s001
Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, vol.76, issue.2, 2013. ,
DOI : 10.1016/j.ijrobp.2009.06.092
Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients, Acta Oncologica, vol.10, issue.3, 2013. ,
DOI : 10.1007/s00535-007-2123-z
Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma, Clinical and Translational Oncology, vol.70, issue.3, pp.218-225, 2010. ,
DOI : 10.1016/j.ijrobp.2007.10.059
Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma, International Journal of Radiation Oncology*Biology*Physics, vol.81, issue.4, pp.447-453, 2011. ,
DOI : 10.1016/j.ijrobp.2011.04.011
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.31, issue.13, pp.1631-1639, 2013. ,
DOI : 10.1200/JCO.2012.44.1659
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma, Cancer, vol.100, issue.3, pp.616-623, 2009. ,
DOI : 10.1093/jnci/djn134
Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib, The Oncologist, vol.19, issue.4, 2014. ,
DOI : 10.1634/theoncologist.2013-0114
Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking, Radiation Oncology, vol.8, issue.1, p.24, 2013. ,
DOI : 10.2214/ajr.165.1.7785638
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Journal of Hepatology, vol.35, issue.3, pp.421-430, 2001. ,
DOI : 10.1016/S0168-8278(01)00130-1
Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma, Cancer, vol.9, issue.2 suppl, pp.3191-3198, 2012. ,
DOI : 10.1053/jlts.2003.50147
Stereotactic Body Radiation Therapy as an Alternative Treatment for Small Hepatocellular Carcinoma, PLoS ONE, vol.12, issue.11, p.79854, 2013. ,
DOI : 10.1371/journal.pone.0079854.t003
Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models, Radiology, vol.262, issue.2, pp.708-718, 2012. ,
DOI : 10.1148/radiol.11110282
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies, Journal of Hepatology, vol.44, issue.1, pp.217-231, 2006. ,
DOI : 10.1016/j.jhep.2005.10.013
Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival, Journal of Clinical Oncology, vol.27, issue.34, pp.5734-5742, 2009. ,
DOI : 10.1200/JCO.2009.23.1282
New Utility of an Old Marker: Serial ??-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy, Journal of Clinical Oncology, vol.27, issue.3, pp.446-452, 2009. ,
DOI : 10.1200/JCO.2008.18.8151
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. The oncologist, juill, vol.14, issue.7, pp.717-725, 2009. ,
Early ??-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma, Liver International, vol.12, issue.3, pp.369-376, 2011. ,
DOI : 10.1038/sj.onc.1209706
Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy, Clinical Radiology, vol.67, issue.5, pp.429-436, 2012. ,
DOI : 10.1016/j.crad.2011.10.009
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma, Journal of Hepatology, vol.57, issue.1, pp.101-107, 2012. ,
DOI : 10.1016/j.jhep.2012.02.016
Radiation Dose???Volume Effects in the Stomach and Small Bowel, International Journal of Radiation Oncology*Biology*Physics, vol.76, issue.3, pp.101-107, 2010. ,
DOI : 10.1016/j.ijrobp.2009.05.071
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases, International Journal of Radiation Oncology*Biology*Physics, vol.62, issue.5, pp.1371-1378, 2005. ,
DOI : 10.1016/j.ijrobp.2005.01.002
Stereotactic Body Radiotherapy for Patients With Unresectable Primary Hepatocellular Carcinoma: Dose-Volumetric Parameters Predicting the Hepatic Complication, International Journal of Radiation Oncology*Biology*Physics, vol.78, issue.4, pp.1073-1080, 2010. ,
DOI : 10.1016/j.ijrobp.2009.09.009
Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters, Radiation Oncology, vol.8, issue.1, p.249, 2013. ,
DOI : 10.1016/j.ijrobp.2004.05.048
Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation, Liver Transplantation, vol.34, issue.8, pp.949-954, 2012. ,
DOI : 10.1097/COC.0b013e3181ec63ae
Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response, Journal of Surgical Oncology, vol.12, issue.7, pp.692-698, 2012. ,
DOI : 10.1016/j.canrad.2008.04.011
Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma. OncoTargets Ther, oct, vol.1527, 2013. ,
Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ???3cm. Results of a multicenter Italian survey, Journal of Hepatology, vol.59, issue.1, pp.89-97, 2013. ,
DOI : 10.1016/j.jhep.2013.03.009
Comparison of Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma after Liver Resection or Transarterial Chemoembolization, PLoS ONE, vol.55, issue.7, p.68193, 2013. ,
DOI : 10.1371/journal.pone.0068193.t004
radiofrequency ablation for hepatocellular carcinoma, World Journal of Gastroenterology, vol.19, issue.26, p.4106, 2013. ,
DOI : 10.3748/wjg.v19.i26.4106
Radiofrequency ablation of liver tumours: systematic review, The Lancet Oncology, vol.5, issue.9, pp.550-560, 2004. ,
DOI : 10.1016/S1470-2045(04)01567-0
Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence, The American Journal of Surgery, vol.200, issue.4, pp.435-439, 2010. ,
DOI : 10.1016/j.amjsurg.2009.11.009
URL : https://hal.archives-ouvertes.fr/hal-00521310
Hepatocellular carcinomas 2???3cm in diameter: Transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone, European Journal of Radiology, vol.81, issue.3, pp.189-193, 2012. ,
DOI : 10.1016/j.ejrad.2011.01.122
Complications of radiofrequency coagulation of liver tumours, British Journal of Surgery, vol.217, issue.10, pp.1206-1222, 2002. ,
DOI : 10.1148/radiology.217.1.r00se02119
Treatment of Focal Liver Tumors with Percutaneous Radio-frequency Ablation: Complications Encountered in a Multicenter Study, Radiology, vol.226, issue.2, pp.441-451, 2003. ,
DOI : 10.1148/radiol.2262012198